Supporting the finding of worse outcomes in GH–PRL PitNETs, Rick et al. [95] reported that double-staining tumor patients were significantly less likely to experience postoperative biochemical remission than single-staining (20.0% vs. 67.9%, p = 0.01) and also had a higher risk of recurrence (18.2% vs. 7%). The gene discussed is PRL; the disease is neoplasm.